Abstract
Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy The interest in aspirin resistance has been increasing during the last few years, with researchers earnestly pursuing alternative anti platelet therapies and devices for measuring platelet aggregation. The recent studies suggest that 5% to 45% of patients taking aspirin do not experience adequate anti platelet effects.
Aspirin resistance has some clinical consequences: In the patients with IHD treated with 100mg of ASA per day, our study has shown that the prevalence of aspirin resistance was 12.1% using CPG method, and 15.3% using PFA-100 method. Aspirin resistance was dose dependent.
Prevalence ASA resistance in patients treated with 200mg of ASA per day was only 7.6% using CPG method.